区分皮质基底节变性所致认知障碍与阿尔茨海默病
本研究比较了尸检证实的皮质基底节变性(CBD,n=17)与阿尔茨海默病(AD,n=16)患者的临床特征。结果显示两者在起病主诉、症状持续时间和基线痴呆严重程度上高度重叠,但CBD患者随后出现不对称运动/感觉体征、反射亢进、步态异常、帕金森综合征、跌倒、尿失禁和眼外肌运动异常等特征,80%的CBD患者在初始评估后3.1年内可检测到≥3个鉴别特征。
要点
- CBD早期可模拟AD痴呆,两者起病表现和基线严重程度重叠明显。
- 不对称运动/感觉体征、反射亢进、步态异常等是鉴别CBD的关键特征。
- 80%的CBD患者在初始评估后3.1年内出现≥3个鉴别特征。
核心结论
- CBD在疾病早期可能模仿AD痴呆,定期筛查鉴别性临床特征有助于提高生前诊断准确性。
研究设计与样本
- 比较尸检证实的CBD(n=17)与AD(n=16)患者的临床特征,所有患者均有显著认知主诉并接受年度半结构化访谈、详细神经系统检查和神经心理测试。
主要发现
- CBD与AD在起病主诉、症状中位持续时间(CBD=3.0年,AD=2.5年,p=0.96)和基线痴呆严重程度(临床痴呆评定量表总分:CBD=3.5,AD=4.25,p=0.49)上存在大量重叠。
- 后续出现的不对称运动/感觉体征、反射亢进、步态异常、帕金森综合征、跌倒、尿失禁和眼外肌运动异常可鉴别CBD,80%的CBD患者在初始评估后3.1年(95%CI 2.9-3.3)内检测到≥3个鉴别特征。
- CBD患者疾病严重程度加重更快,情景记忆、执行功能和字母流畅性下降更显著。
- 半定量病理评估显示CBD病例额叶和顶叶有显著tau病理;59%(10/17)的CBD病例合并AD神经病理改变,但与临床表型、痴呆进展速度或痴呆持续时间无关。
临床怎么用
- 对以显著认知症状为主的CBD疑似患者,应定期筛查不对称运动/感觉体征、反射亢进、步态异常、帕金森综合征、跌倒、尿失禁和眼外肌运动异常等鉴别特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify clinical features that reliably differentiate individuals with cognitive impairment due to corticobasal degeneration (CBD) and Alzheimer disease (AD). METHODS: Clinical features were compared between individuals with autopsy-proven CBD (n = 17) and AD (n = 16). All individuals presented with prominent cognitive complaints and were evaluated annually with semistructured interviews, detailed neurologic examinations, and neuropsychological testing. RESULTS: Substantial overlap was observed between individuals with dementia due to CBD and AD concerning presenting complaints, median (range) duration of symptoms before assessment (CBD = 3.0 [0-5.0] years, AD = 2.5 [0-8.0] years; p = 0.96), and median (range) baseline dementia severity (Clinical Dementia Rating Sum of Boxes: CBD = 3.5 [0-12.0], AD = 4.25 [0.5-9.0], p = 0.49). Subsequent emergence of asymmetric motor/sensory signs, hyperreflexia, gait abnormalities, parkinsonism, falls, urinary incontinence, and extraocular movement abnormalities identified individuals with CBD, with ≥3 discriminating features detected in 80% of individuals within 3.1 years (95% confidence interval 2.9-3.3) of the initial assessment. Individuals with CBD exhibited accelerated worsening of illness severity and declines in episodic memory, executive functioning, and letter fluency. Semiquantitative pathologic assessment revealed prominent tau pathology within the frontal and parietal lobes of CBD cases. Comorbid AD neuropathologic change was present in 59% (10 of 17) of CBD cases but did not associate with the clinical phenotype, rate of dementia progression, or dementia duration. CONCLUSIONS: CBD may mimic AD dementia early in its disease course. Interval screening for discriminating clinical features may improve antemortem diagnosis in individuals with CBD and prominent cognitive symptoms.
引用
- Day GS, Lim TS, Hassenstab J, et al. Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology. 2017. PMID: 28235814. doi:10.1212/WNL.0000000000003770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。